Vitamin D treatment modulates immune activation in cystic fibrosis.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a clinical trial.

Persistent inflammatory response in cystic fibrosis (CF) airways is believed to play a central role in the progression of lung damage.

Anti-inflammatory treatment may slow lung disease progression, but adverse side effects have limited its use.

Who Took Part

The abstract describes 16 patients taking part.

PubMed indexes the participants as children and teenagers, both men and women.

Three months of vitamin D treatment were followed by two washout months.

How the Study Was Run

The design is described as randomized and pilot.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

It is described as a pilot, a small early test of whether a larger Vitamin D, K2, Magnesium and Zinc study would be practical.

What Was Measured

Topics PubMed links to this paper include ADP-ribosyl Cyclase 1, B7-2 Antigen, CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, Cholecalciferol, Cystic Fibrosis and Dendritic Cells.

The authors tagged it with the keywords T cells, immunity, immunoglobulins and vitamin D.

What This Means in Plain Language

The paper is a randomized and pilot study of Vitamin D, K2, Magnesium and Zinc in 16 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2017 (Clinical and experimental immunology), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.